Division of Medical Treatment and Rehabilitation

Top > Medical Treatment and Rehabilitation

Publication

PUBLICATIONS (Peer-Reviewed Journal)

  1. Nakamura K., Sekine Y., Ouchi Y., Tsujii M., Yoshikawa E., Futatsubashi M., Tsuchiya K.J., Sugihara G., Takebayashi K., Iwata Y., Suzuki K., Suda S., Matsuzaki H., Sugiyama T., Takei N., Mori N. (in press) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch. Gen. Psychiatry.
  2. Nakamura K., Sekine Y., Takei N., Iwata Y., Suzuki K., Anitha A., Inada T., Harano M., Komiyama T., Yamada M., Iwata N., Iyo M., Sora I., Ozaki N., Ujike H., Mori N. (2009) An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis. Neurosci. Lett. 15:120-123.
  3. Anitha A., Nakamura K., Yamada K., Iwayama Y., Toyota T., Takei N., Iwata Y., Suzuki K., Sekine Y., Matsuzaki H., Kawai M., Thanseem I., Miyoshi K., Katayama T., Matsuzaki S., Baba K., Honda A., Hattori T., Shimizu S., Kumamoto N., Kikuchi M., Tohyama M., Yoshikawa T., Mori N. Association studies and gene expression analyses of the DISC1-interacting molecules, pericentrin 2 (PCNT2) and DISC1-binding zinc finger protein (DBZ), with schizophrenia and with bipolar disorder. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B:967-976.
  4. Kanahara N., Miyatake R., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M., Hashimoto K. (2009) Association study between the PIK4CA gene and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B:233-238.
  5. Iwata Y., Tsuchiya K.J., Mikawa S., Nakamura K., Takai Y., Suda S., Sekine Y., Suzuki K., Kawai M., Sugihara G., Matsuzaki H., Hashimoto K., Tsujii M., Sugiyama T., Takei N., Mori N. Serum levels of P-selectin in men with high-functioning autism. (2008) Br. J. Psychiatry. 193, 338-339.
  6. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M. Sora I., Sekine Y., Ozaki N., Ujike H., Iwata N. (2008) Prostate apoptosis response 4 gene is not associated with methamphetamine-use disorder in the Japanese population. (2008) Ann. N. Y. Acad. Sci. 1139:83-88.
  7. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M., Sora I., Sekine Y., Ozaki N., Ujike H., Iwata N. a4 and b2 subunits of neuronal nicotinic acetylcholine receptor genes are not associated with methamphetamine-use disorder in the Japanese population. (2008) Ann. N. Y. Acad. Sci. 1139:70-82.
  8. Kishi T., Ikeda M., Kitajima T., Yamanouchi Y., Kinoshita Y., Kawashima K., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Iyo M., Sora I., Sekine Y., Ozaki N., Ujike H., Iwata N. (2008) Glutamate cysteine ligase modifier (GCLM) subunit gene is not associated with methamphetamine-use disorder or schizophrenia in the Japanese population. Ann. N. Y. Acad. Sci. 1139:63-69.
  9. Kinoshita Y., Ikeda M., Ujike H., Kitajima T., Yamanouchi Y., Aleksic B., Kishi T., Kawashima K., Ohkouchi T., Ozaki N., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iyo M., Sora I., Iwata N. (2008) Association study of the calcineurin A g subunit gene (PPP3CC) and methamphetamine-use disorder in a Japanese population. Ann. N. Y. Acad. Sci. 1139:57-62.
  10. Ezaki N., Nakamura K., Sekine Y., Thanseem I., Anitha A., Iwata Y., Kawai M., Takebayashi K., Suzuki K., Takei N., Iyo M., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Mori N. (2008) Short allele of 5-HTTLPR as a risk factor for the development of psychosis in Japanese methamphetamine abusers. Ann. N. Y. Acad. Sci. 1139:49-56.
  11. Kotaka T., Ujike H., Morita Y., Kishimoto M., Okahisa Y., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. (2008) Association study between casein kinase 1 epsilon gene and methamphetamine dependence. Ann. N. Y. Acad. Sci. 1139:43-48.
  12. Nakamura K., Anitha A., Yamada K., Tsujii M., Iwayama Y., Hattori E., Toyota T., Suda S., Takei N., Iwata Y., Suzuki K., Matsuzaki H., Kawai M., Sekine Y., Tsuchiya K.J., Sugihara G.I., Ouchi Y., Sugiyama T., Yoshikawa T. Mori N. (2008) Genetic and expression analyses reveal elevated expression of syntaxin 1A (STX1A) in high functioning autism. Int. J. Neuropsychopharmacol. 11:1073-1084.
  13. Sekine Y., Ouchi Y., Sugihara G., Takei N., Yoshikawa E., Nakamura K., Iwata Y., Tsuchiya K.J., Suda S., Suzuki K., Kawai M., Takebayashi K., Yamamoto S., Matsuzaki H., Ueki T., Mori N., Gold M.S., Cadet J.L. (2008) Methamphetamine causes microglial activation in the brains of human abusers. J. Neurosci. 28, 5756-5761.
  14. Uhl G.R., Drgon T., Liu Q.R., Johnson C., Walther D., Ujike H., Komiyama T., Harano M., Sekine Y., Inada T., Ozaki N., Iyo M., Iwata N., Yamada M., Sora I., Chen C.K., Liu H.C., Lin S.K. (2008) Genome-wide association for methamphetamine dependence. Convergent results from two samples. Arch. Gen. Psychiatry. 65, 345-355.
  15. Hashimoto T., Hashimoto K., Miyatake R., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M. (2008) Association study between polymorphisms in glutathione-related genes and methamphetamine use disorder in a Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B:1040-1046.
  16. Iwata Y., Tsuchiya K.J., Mikawa S., Nakamura K., Takai Y., Suda S., Sekine Y., Suzuki K., Kawai M., Sugihara G., Matsuzaki H., Hashimoto K., Tsujii M., Sugiyama T., Takei N., Mori N. (2008) Decreased serum levels of soluble P-selectin in patients with high-functioning autism were correlated negatively with abnormal social development in early life and positively with head circumference at birth. Br. J. Psychiatry. 193, 338-339.
  17. Tsuchiya K.J., Matsumoto K., Miyachi T., Tsujii M., Nakamura K., Takagai S., Kawai M., Yagi A., Iwaki K., Suda S., Sugihara G., Iwata Y., Matsuzaki H., Sekine Y., Suzuki K., Sugiyama T., Mori N., Takei N. (2008) Serum levels of P-selectin in men with high-functioning autism. Br. J. Psychiatry. 193:316-321.
  18. Anitha A., Nakamura K., Yamada K., Iwayama Y., Toyota T., Takei N., Iwata Y., Suzuki K., Sekine Y., Matsuzaki H., Kawai M., Miyoshi K., Katayama T., Matsuzaki S., Baba K., Honda A., Hattori T., Shimizu S., Kumamoto N., Tohyama M., Yoshikawa T., Mori N. (2008) Gene and expression analyses reveal enhanced expression of pericentrin 2 (PCNT2) in bipolar disorder. Biol. Psychiatry 63, 678-685.
  19. Suzuki K., Nakamura K., Iwata Y., Sekine Y., Kawai M., Sugihara G., Tsuchiya K.J., Suda S., Matsuzaki H., Takei N., Hashimoto K., Mori N. (2008) Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophr. Res. 98, 148-156.
  20. Otani K., Ujike H., Sakai A., Okahisa Y., Kotaka T., Inada T., Harano M., Komiyama T., Hori T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. (2008) Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence. Neurosci. Lett. 434, 88-92.
  21. Kishimoto M., Ujike H., Motohashi Y., Tanaka Y., Okahisa Y., Kotaka T., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2008) The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. Biol. Psychiatry. 63.191-196.
  22. Tsuchiya K.J., Hashimoto K., Iwata Y., Tsujii M., Sekine Y., Sugihara G., Matsuzaki H., Suda S., Kawai M., Nakamura K., Minabe Y., Yagi A., Iyo M., Takei N., Mori N. (2007) Decreased serum levels of PECAM-1 in subjects with high-functioning autism. A negative correlation with head circumference at birth. Biol. Psychiatry. 62, 1056-1058.
  23. Toyoda T., Nakamura K., Yamada K., Thanseem I., Anitha A., Suda S., Tsujii M., Iwayama Y., Hattori E., Toyota T., Miyachi T., Iwata Y, Suzuki K, Matsuzaki H., Kawai M, Sekine Y., Tsuchiya K., Sugihara G., Ouchi Y., Sugiyama T., Takei N., Yoshikawa T., Mori N. (2007) SNP analyses of growth factor genes EGF, TGFb-1, and HGF reveal haplotypic association of EGF with autism. Biochem. Biophys. Res. Commun. 360, 715-720.
  24. Matsuzawa D., Hashimoto K., Miyatake R., Shirayama Y., Shimizu E., Maeda K., Suzuki Y., Mashimo Y., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Hata A., Sawa A., Iyo M. (2007) Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am. J. Psychiatry. 164, 1105-1114.
  25. Matsuzaki H., Minabe Y., Nakamura K., Suzuki K., Iwata Y., Sekine Y., Tsuchiya K.J., Sugihara G., Suda S., Takei N., Nakahara D., Hashimoto K., Nairn A.C., Mori N., Sato K. (2007) Disruption of reelin signaling attenuates methamphetamine-induced hyperlocomotion. Eur. J. Neurosci. 25, 3376-3384.
  26. Suzuki K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suda S., Sugihara G., Matsuzaki H., Sugiyama T., Kawai M., Minabe Y., Takei N., Mori N. (2007) Decreased serum levels of epidermal growth factor in adult subjects with high-functioning autism. Biol. Psychiatry. 62, 267-269.
  27. Sekine Y., Suzuki K., Ramachandran P.V., Blackburn T.P., Ashby C.R. Jr. (2007) Acute and repeated administration of fluoxetine, citalopram, and paroxetine significantly alters the activity of midbrain dopamine neurons in rats. An in vivo electrophysiological study. Synapse 61, 72-77.
  28. Sugihara G., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suzuki K., Suda S., Matsuzaki H., Kawai M., Minabe Y., Yagi A., Takei N., Sugiyama T., Mori N. (2007) Decreased serum levels of hepatocyte growth factor in male adults with high-functioning autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 31, 412-415.
  29. Iwata Y., Nakajima M., Yamada K., Nakamura K., Sekine Y., Tsuchiya K.J., Sugihara G., Matsuzaki H., Suda S., Suzuki K., Takei N., Mori N., Iwayama Y., Takao H., Yoshikawa T., Riley B., Makoff A., Sham P., Chen R., Collier D. (2007) Linkage disequilibrium analysis of the CHRNA7 gene and its partially duplicated region in schizophrenia. Neurosci. Res. 57, 194-202.
  30. Iwata Y., Suzuki K., Nakamura K., Matsuzaki H., Sekine Y., Tsuchiya K.J., Sugihara G., Kawai M., Minabe Y., Takei N., Mori N. (2007) Increased levels of serum soluble L-selectin in unmedicated patients with schizophrenia. Schizophr. Res. 89, 154-160.
  31. Nishimura K., Nakamura K., Anitha A., Yamada K., Tsujii M., Iwayama Y., Hattori E., Toyota T., Takei N., Miyachi T., Iwata Y., Suzuki K., Matsuzaki H., Kawai M., Sekine Y., Tsuchiya K., Sugihara G., Suda S., Ouchi Y., Sugiyama T., Yoshikawa T., Mori N. (2007) Genetic analyses of the brain-derived neurotrophic factor (BDNF) gene in autism. Biochem. Biophys. Res. Commun. 356, 200-206.
  32. Okada K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suda S., Suzuki K., Sugihara G., Matsuzaki H., Sugiyama T., Kawai M., Minabe Y., Takei N., Mori N. (2007) Decreased serum levels of transforming growth factor-b1 in patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 187-190.
  33. Nishimura K., Takei N., Suzuki K., Kawai M., Sekine Y., Isoda H., Mori N. (2006) A transient lesion in splenium of the corpus callosum in a patient with childhood-onset anorexia nervosa. Int. J. Eat. Disord. 39, 527-529.
  34. Ikeda M., Ozaki N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Kishi T., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Iwata N. (2007) Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes. Brain. Behav. 6, 107-112.
  35. Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suzuki K., Minabe Y., Takei N., Iyo M., Mori N. Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. (2006) Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry. 30, 1529-1531.
  36. Morio A., Ujike H., Nomura A., Tanaka Y., Morita Y., Otani K., Kishimoto M., Harano M., Inada T., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. (2006) No association between CART (cocaine- and amphetamine-regulated transcript) gene and methamphetamine dependence. Ann. N. Y. Acad. Sci. 1074, 411-417.
  37. Nomura A., Ujike H., Tanaka Y., Kishimoto M., Otani K., Morita Y., Morio A., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2006) Association study of the tumor necrosis factor-alpha gene and its 1A receptor gene with methamphetamine dependence. Ann. N. Y. Acad. Sci. 1074, 116-124.
  38. Ujike H., Sakai A., Nakata K., Tanaka Y., Kodaka T., Okahisa Y., Harano M., Inada T., Yamada M., Komiyama T., Hori T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2006) Association study of the dihydropyrimidinase-related protein 2 gene and methamphetamine psychosis. Ann. N. Y. Acad. Sci. 1074, 90-96.
  39. Aoyama N., Takahashi N., Kitaichi K., Ishihara R., Saito S., Maeno N., Ji X., Takagi K., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iwata N., Inada T., Ozaki N. (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin. Exp. Res. 30, 1644-1649.
  40. Shinohe A., Hashimoto K., Nakamura K., Tsujii M., Iwata Y., Tsuchiya K.J., Sekine Y., Suda S., Suzuki K., Sugihara G., Matsuzaki H., Minabe Y., Sugiyama T., Kawai M., Iyo M., Takei N., Mori N. Increased serum levels of glutamate in adult patients with autism. (2006) Prog. Neuropsychopharmacol. Biol. Psychiatry. 30, 1472-1477.
  41. Kobayashi H., Hata H., Ujike H., Harano M., Inada T., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Ozaki N., Itokawa M., Naka M., Ide S., Ikeda K., Numachi Y., Sora I. (2006) Association analysis of d-opioid receptor gene polymorphisms in methamphetamine dependence/psychosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 482-486.
  42. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Okada H., Minabe Y., Nakamura K., Suzuki K., Iwata Y., Tsuchiya K.J., Sugihara G., Mori N. (2006) Perospirone is a new generation antipsychotic. Evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. J. Clin. Psychopharmacol. 26, 531-533.
  43. Suzuki A., Nakamura K., Sekine Y., Minabe Y., Takei N., Suzuki K., Iwata Y., Kawai M., Takebayashi K., Matsuzaki H., Iyo M., Ozaki N., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Mori N. (2006) An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiatr. Genet. 16, 133-138.
  44. Nakamura K., Yamada K., Iwayama Y., Toyota T., Furukawa A., Takimoto T., Terayama H., Iwahashi K., Takei N., Minabe Y., Sekine Y., Suzuki K., Iwata Y., Pillai A., Nakamoto Y., Ikeda K., Yoshii M., Fukunishi I., Yoshikawa T., Mori N. (2006) Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 222-226.
  45. Ide S., Kobayashi H., Ujike H., Ozaki N., Sekine Y., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Iwata N., Tanaka K., Shen H., Iwahashi K., Itokawa M., Minami M., Satoh M., Ikeda K., Sora I. (2006) Linkage disequilibrium and association with methamphetamine dependence/psychosis of m-opioid receptor gene polymorphisms. Pharmacogenomics J. 6, 179-188.
  46. Yoshitsugu K., Yamada K., Toyota T., Aoki-Suzuki M., Minabe Y., Nakamura K., Sekine Y., Suzuki K., Takei N., Itokawa M., Mori N., Yoshikawa T. (2006) A novel scale including strabismus and 'cuspidal ear' for distinguishing schizophrenia patients from controls using minor physical anomalies. Psychiatry Res. 145, 249-258.
  47. Nakamura K., Chen C.K., Sekine Y., Iwata Y., Anitha A., Loh el-W., Takei N., Suzuki A., Kawai M., Takebayashi K., Suzuki K., Minabe Y., Tsuchiya K., Yamada K., Iyo M., Ozaki N., Inada T., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Ball D.M., Yoshikawa T., Lin S.K., Mori N. (2006) Association analysis of SOD2 variants with methamphetamine psychosis in Japanese and Taiwanese populations. Hum. Genet. 120, 243-252.
  48. Nomura A., Ujike H., Tanaka Y., Otani K., Morita Y., Kishimoto M., Morio A., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Iwata N., Sora I., Iyo M., Ozaki N., Kuroda S. (2006) Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence. Neurosci. Lett. 400, 158-162.
  49. Sekine Y., Ouchi Y., Takei N., Yoshikawa E., Nakamura K., Futatsubashi M., Okada H., Minabe Y., Suzuki K., Iwata Y., Tsuchiya K.J., Tsukada H., Iyo M., Mori N. (2006) Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch. Gen. Psychiatry. 63, 90-100.
  50. Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshiya Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Ozaki N. (2006) Positive association of AKT1 haplotype to Japanese methamphetamine use disorder. Int. J. Neuropsychopharmacol. 9, 77-81.
  51. Sekine Y., Takei N., Suzuki K., Nakamura K., Tsuchiya K.J., Takebayashi K., Toulopoulou T., Mori N. (2005) Effective adjunctive use of pergolide with quetiapine for cognitive impairment and negative symptoms in schizophrenia. J. Clin. Psychopharmacol. 25, 281-283.
  52. Morita Y., Ujike H., Tanaka Y., Uchida N., Nomura A., Ohtani K., Kishimoto M., Morio A., Imamura T., Sakai A., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N., Kuroda S. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. (2005) Neurosci. Lett. 376, 182-187.
  53. Ohgake S., Hashimoto K., Shimizu E., Koizumi H., Okamura N., Koike K., Matsuzawa D., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Shirayama Y., Iyo M. (2005) Functional polymorphism of the NQO2 gene is associated with methamphetamine psychosis. Addict. Biol. 10, 145-148.
  54. Nishiyama T., Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Sekine Y., Iyo M., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Inada T., Furukawa T., Ozaki N. (2005) Haplotype association between GABAA receptor ?2 subunit gene (GABRG2) and methamphetamine use disorder. Pharmacogenomics J. 5, 89-95.
  55. Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T. (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175.
  56. Morita Y., Ujike H., Tanaka Y., Uchida N., Nomura A., Otani K., Kishimoto M., Morio A., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iwata N., Iyo M., Sora I., Ozaki N (2005). The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence. Neurosci. Lett. 383, 194-198.
  57. Hashimoto T., Hashimoto K., Matsuzawa D., Shimizu E., Sekine Y., Inada T., Ozaki N., Iwata N., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Iyo M. (2005) A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 135, 5-9.
  58. Itoh K., Hashimoto K., Shimizu E., Sekine Y., Ozaki N., Inada T., Harano M., Iwata N., Komiyama T., Yamada M., Sora I., Nakata K., Ujike H., Iyo M. (2005) Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132, 70-73.
  59. Ouchi Y., Yoshikawa E., Kanno T., Futatsubashi M., Sekine Y., Okada H., Torizuka T., Tanaka K. (2005) Orthostatic posture affects brain hemodynamics and metabolism in cerebrovascular disease patients with and without coronary artery disease. A positron emission tomography study. Neuroimage. 24, 70-81.
  60. Kobayashi H., Ide S., Hasegawa J., Ujike H., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Shen H.W., Ikeda K., Sora I. (2004) Study of association a-synuclein gene polymorphism and methamphetamine psychosis/dependence. Ann. N. Y. Acad. Sci. 1025, 325-334.
  61. Ide S., Kobayashi H., Tanaka K., Ujike H., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Iyo M., Ikeda K., Sora I. (2004) Gene polymorphisms of the m opioid receptor in methamphetamine abusers. Ann. N. Y. Acad. Sci. 1025, 316-324.
  62. Harano M., Uchimura N., Abe H., Ishibashi M., Iida N., Yanagimoto K., Tanaka T., Maeda H., Sora I., Iyo M., Komiyama T., Yamada M., Sekine Y., Inada T., Ozaki N., Ujike H. (2004) A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis. Ann. N. Y. Acad. Sci. 1025, 307-315.
  63. Iyo M., Sekine Y., Mori N. (2004) Neuromechanism of developing methamphetamine psychosis. A neuroimaging study. Ann. N. Y. Acad. Sci. 1025, 288-295.
  64. Iwata N., Inada T., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujike H., Ozaki N. (2004) No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder. a collaborative study by the Japanese genetic initiative for drug abuse. Ann. N. Y. Acad. Sci. 1025, 34-38.
  65. Inada T., Iijima Y., Uchida N., Maeda T., Iwashita S., Ozaki N., Harano M., Komiyama T., Yamada M., Sekine Y., Iyo M., Sora I., Ujike H. (2004) No association found between the type 1 s receptor gene polymorphisms and methamphetamine abuse in the Japanese population. a collaborative study by the Japanese genetic initiative for drug abuse. Ann. N. Y. Acad. Sci. 1025, 27-33.
  66. Yamada K., Nakamura K., Minabe Y., Iwayama-Shigeno Y., Takao H., Toyota T., Hattori E., Takei N., Sekine Y., Suzuki K., Iwata Y., Miyoshi K., Honda A., Baba K., Katayama T., Tohyama M., Mori N., Yoshikawa T. (2004) Association analysis of FEZ1 variants with schizophrenia in Japanese cohorts. Biol. Psychiatry. 56, 683-690.
  67. Takebayashi K., Sekine Y., Takei N., Minabe Y., Isoda H., Takeda H., Nishimura K., Nakamura K., Suzuki K., Iwata Y., Sakahara H., Mori N. (2004) Metabolite alterations in basal ganglia associated with psychiatric symptoms of abstinent toluene users. A proton MRS study. Neuropsychopharmacology. 29, 1019-1026.
  68. Toyota T., Yoshitsugu K., Ebihara M., Yamada K., Ohba H., Fukasawa M., Minabe Y., Nakamura K., Sekine Y., Takei N., Suzuki K., Itokawa M., Meerabux J.M., Iwayama-Shigeno Y., Tomaru Y., Shimizu H., Hattori E., Mori N., Yoshikawa T. (2004) Association between schizophrenia with ocular misalignment and polyalanine length variation in PMX2B. Hum. Mol. Genet. 13, 551-561.
  69. Suzuki K., Takei N., Iwata Y., Sekine Y., Toyoda T., Nakamura K., Minabe Y., Kawai M., Iyo M., Mori N. (2004) Do olfactory reference syndrome and Jiko-shu-kyofu (a subtype of Taijin-kyofu) share a common entity? Acta. Psychiatr. Scand. 109, 150-155.
  70. Sekizawa T., Iwata Y., Nakamura K., Matsumoto H., Suzuki A., Suzuki K., Sekine Y., Takei N., Minabe Y., Mori N. Childhood-onset schizophrenia and tryptophan hydroxylase gene polymorphism. (2004) Am. J. Med. Genet. B Neuropsychiatr. Genet. 132, 70-73.
  71. Koizumi H., Hashimoto K., Kumakiri C., Shimizu E., Sekine Y., Ozaki N., Inada T., Harano M., Komiyama T., Yamada M., Sora I., Ujike H., Takei N., Iyo M. (2004) Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 126, 43-45.
  72. Tani K., Takei N., Kawai M., Suzuki K., Sekine Y., Toyoda T., Minabe Y., Mori N. (2004) Augmentation of milnacipran by risperidone in treatment for major depression. Int. J. Neuropsychopharmacol. 7, 1-4.
  73. Won M., Minabe Y., Sekine Y., Takei N., Kondo N., Mori N. (2003) Manic-switch induced by fluvoxamine in abstinent pure methamphetamine abusers. J. Psychiatry. Neurosci. 28, 134-135.
  74. Nakamura K., Iwahashi K., Furukawa A., Ameno K., Kinoshita H., Ijiri I., Sekine Y., Suzuki K., Iwata Y., Minabe Y., Mori N. (2003) Acetaldehyde adducts in the brain of alcoholics. Arch. Toxicol. 77, 591-593.
  75. Sekine Y., Minabe Y., Ouchi Y., Takei N., Iyo M., Nakamura K., Suzuki K., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Mori N. (2003) Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am. J. Psychiatry. 160, 1699-1701.
  76. Ujike H., Harano M., Inada T., Yamada M., Komiyama T., Sekine Y., Sora I., Iyo M., Katsu T., Nomura A., Nakata K., Ozaki N. (2003) Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics. J. 3, 242-247.
  77. Won M., Minabe Y., Tani K., Suzuki K., Kawai M., Sekine Y., Ashby C.R. Jr., Takei N., Mori N (2003). The effects of dentate granule cell destruction on behavioral activity and Fos protein expression induced by systemic MDMA in rats. Neurosci. Res. 46,153-160.
  78. Nakamura K., Iwahashi K., Ameno K., Sekine Y., Suzuki K., Minabe Y., Mori N. (2003) CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 47, 86-89.
  79. Iwata Y., Matsumoto H., Minabe Y., Osada N., Nakamura K., Sekizawa T., Suzuki K., Sekine Y., Takei N., Mori N. (2003) Early-onset schizophrenia and dopamine-related gene polymorphism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116, 23-26.
  80. Sakanoue M., Mori N., Takei N., Kawai M., Tani K., Suzuki K., Iwata Y., Sekine Y., Ashby C.R. Jr., Minabe Y. Tacrolimus, a specific inhibitor of calcineurin, modifies the locomotor activity of quinpirole, but not that of SKF82958, in male rats. (2002) Eur. J. Pharmacol. 438, 93-97.
  81. Sekine Y., Minabe Y., Kawai M., Suzuki K., Iyo M., Isoda H., Sakahara H., Ashby C.R. Jr., Takei N., Mori N. (2002) Metabolite alterations in basal ganglia associated with methamphetamine-related psychiatric symptoms. A proton MRS study. Neuropsychopharmacology. 27, 453-461.
  82. Matsunaga T., Tsukada H., Nishiyama S., Sekine Y., Kakiuchi T., Iyo M., Mori N. (2001) Yohimbine increases the binding potential for [11C] flumazenil in the monkey brain. J. Neural. Transm. 108, 1375-1382.
  83. Tani K., Iyo M., Matsumoto H., Kawai M., Suzuki K., Iwata Y., Won T., Tsukamoto T., Sekine Y., Sakanoue M., Hashimoto K., Ohashi Y., Takei N., Mori N. (2001) The effects of dentate granule cell destruction on behavioural activity and Fos protein expression induced by systemic methamphetamine in rats. Br. J. Pharmacol. 134, 1411-1418.
  84. Suzuki K., Omura S., Ohashi Y., Kawai M., Iwata Y., Tani K., Sekine Y., Takei N., Mori N. (2001) FK506 facilitates chemical kindling induced by pentylenetetrazole in rats. Epilepsy. Res. 46, 279-282.
  85. Tsukamoto T., Iyo M., Tani K., Sekine Y., Hashimoto K., Ohashi Y., Suzuki K., Iwata Y., Mori N. (2001) The effects of FK506, a specific calcineurin inhibitor, on methamphetamine-induced behavioral change and its sensitization in rats. Psychopharmacology. 158, 107-113.
  86. Sekine Y., Takei N., Iyo M., Mori N., Minami M., Ohta T. (2001) Effective risperidone treatment for simple deteriorative disorder (simple schizophrenia). A case report. Schizophr. Res. 50, 213-214.
  87. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., Mori N. (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am. J. Psychiatry. 158, 1206-1214.
  88. Sekine Y., Iyo M., Tanaka K., Matsuyama K., Matsunaga T., Mori N. (2000) Effective adjunctive use of low-dose methylphenidate with mianserin for major depression with silent cerebral infarction. A case report. J. Clin. Psychopharmacol. 20, 584-585.
  89. Iyo M., Sekine Y., Matsunaga T., Tsukamoto T., Takei N., Mori N: Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report. (1999) J. Clin. Psychiatry. 60, 337-338.
  90. Ouchi Y., Yoshikawa E., Okada H., Futatsubashi M., Sekine Y., Iyo M., Sakamoto M: Alterations in binding site density of dopamine transporter in the striatum,orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for b-CFT binding with positron emission tomography. (1999) Ann. Neurol. 45, 601-610.

AWARDS

  1. Dr Paul Janssen Research Award - The Japanese Society of Clinical Neuropsychopharmacology (2006)
  2. Research Award for Young Scientist - The Japan Brain Science Society (2004)
  3. Research Award for Young Scientist - The Public Health Research Foundation/New Frontiers of Neurotransmitter Research (2003)
  4. Dr Paul Janssen Research Award - The Japanese Society of Clinical Neuropsychopharmacology (2002)
  5. Research Award - The Japanese Society of Biological Psychiatry (2002)
  6. Dr Kenjiro Takayanagi Research Award for Young Scientist - Hamamatsu Electronics Promotion Association (2001)
  7. Travel Award - The Japanese Society of Biological Psychiatry (2001)

Page Top